Communiqués Krystal Biotech, Inc.

Actions

KRYS

US5011471027

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 05/10/2026			Varia. 5j.	Varia. 1 janv.
334,85 ^USD	+3,90%		-0,66%	+35,82%

21/09	Krystal Biotech, Inc. : BofA Securities réitère son opinion positive sur le titre	ZM
08/09	Un dirigeant de Krystal Biotech cède des actions pour une valeur de 8 983 084 $, selon un récent document de la SEC	MT

Communiqués

03/09	Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference	AQ
03/08	Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results	AQ
23/07	Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026	AQ
18/05	Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa	AQ
07/05	Krystal Biotech to Present at BofA Securities 2026 Health Care Conference	AQ
04/05	Krystal Biotech : First Quarter 2026 Earnings Call	PU
04/05	Krystal Biotech Announces First Quarter 2026 Financial and Operating Results	AQ
30/04	Krystal Biotech to Present at Upcoming Scientific Conferences	AQ
21/04	Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026	AQ
24/02	Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference	AQ
17/02	Krystal Biotech : Fourth Quarter and Full Year 2025 Financial and Operating Results - Presentation	PU
17/02	Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results	AQ
10/02	Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026	AQ
09/02	Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer	AQ
11/01	Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference	AQ
09/01	Krystal Biotech : KB407 Clinical Data Update	PU
08/01	Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis	AQ
07/01	Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis	AQ
05/01	Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference	AQ
26/11	Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference	AQ
03/11	Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results	AQ
21/10/25	Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025	AQ
14/10/25	Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis	AQ
15/09/25	Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label	AQ
02/09/25	Krystal Biotech to Present at Cantor Global Healthcare Conference 2025	AQ